KCM
KRRO icon

Kennedy Capital Management’s Korro Bio KRRO Stock Holding History

Kennedy Capital Management’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-959
Closed -$456K – 650
2021
Q1 		$456K Buy
+959
New +$1.86M 0.01% 611

Other funds holding KRRO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Kennedy Capital Management's KRRO Position: Q2 2021 in Review

Kennedy Capital Management sold out of Korro Bio (KRRO) in Q2 2021, closing a stake of 959 shares — an estimated $456K sold.

Kennedy Capital Management first reported a position in KRRO in Q1 2021 and held it in 1 quarter. The position peaked at $456K in Q1 2021. 91 funds tracked by Wall St. Rank hold KRRO as of Q2 2021.

  • Kennedy Capital Management reported no remaining Korro Bio position as of Q2 2021 after selling out during the quarter.
  • Kennedy Capital Management sold 959 Korro Bio shares in Q2 2021, an estimated $456K.
  • Kennedy Capital Management first reported a position in Korro Bio in Q1 2021 and held it in 1 quarter.
  • Kennedy Capital Management's Korro Bio position peaked at $456K in Q1 2021.
  • 91 funds tracked by Wall St. Rank held Korro Bio as of Q2 2021.

Based on Kennedy Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.